Candel Therapeutics, Inc. financial data

Symbol
CADL on Nasdaq
Location
Needham, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 746% % 249%
Debt-to-equity 42% % -86%
Return On Equity -51% % 89%
Return On Assets -36% % 69%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 73,246,927 shares 55%
Common Stock, Shares, Outstanding 54,898,303 shares 17%
Entity Public Float $245,300,000 USD 51%
Common Stock, Value, Issued $550,000 USD 17%
Weighted Average Number of Shares Outstanding, Basic 52,958,644 shares 67%
Weighted Average Number of Shares Outstanding, Diluted 52,958,644 shares 67%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $30,496,000 USD 58%
General and Administrative Expense $17,770,000 USD 26%
Operating Income (Loss) $48,266,000 USD -45%
Nonoperating Income (Expense) $10,084,000 USD -132%
Net Income (Loss) Attributable to Parent $38,182,000 USD 31%
Earnings Per Share, Basic -0.72 USD/shares 59%
Earnings Per Share, Diluted -0.72 USD/shares 59%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $119,731,000 USD 17%
Assets, Current $121,389,000 USD 17%
Property, Plant and Equipment, Net $1,642,000 USD -25%
Operating Lease, Right-of-Use Asset $1,661,000 USD 206%
Assets $125,195,000 USD 17%
Accounts Payable, Current $1,129,000 USD 376%
Employee-related Liabilities, Current $3,384,000 USD 11%
Accrued Liabilities, Current $7,334,000 USD 43%
Liabilities, Current $8,997,000 USD -76%
Operating Lease, Liability, Noncurrent $1,459,000 USD 258%
Liabilities $73,273,000 USD 81%
Retained Earnings (Accumulated Deficit) $230,387,000 USD -20%
Stockholders' Equity Attributable to Parent $51,922,000 USD -22%
Liabilities and Equity $125,195,000 USD 17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,616,000 USD -2.1%
Net Cash Provided by (Used in) Financing Activities $1,870,000 USD -49%
Net Cash Provided by (Used in) Investing Activities $3,000 USD 57%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 55,020,911 shares 17%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,489,000 USD -8.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $120,147,000 USD 17%
Interest Paid, Excluding Capitalized Interest, Operating Activities $252,000 USD -54%
Deferred Tax Assets, Valuation Allowance $65,268,000 USD 25%
Deferred Tax Assets, Gross $65,706,000 USD 25%
Operating Lease, Liability $1,904,000 USD 96%
Depreciation $845,000 USD -15%
Payments to Acquire Property, Plant, and Equipment $3,000 USD -57%
Lessee, Operating Lease, Liability, to be Paid $2,285,000 USD 122%
Property, Plant and Equipment, Gross $5,200,000 USD -1.3%
Operating Lease, Liability, Current $445,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Two $613,000 USD 48%
Lessee, Operating Lease, Liability, to be Paid, Year One $618,000 USD 0.82%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $381,000 USD 593%
Lessee, Operating Lease, Liability, to be Paid, Year Three $628,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $37,934,000 USD 27%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $426,000 USD
Operating Lease, Payments $613,000 USD 2.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $438,000 USD 58%
Share-based Payment Arrangement, Expense $3,817,000 USD -28%
Interest Expense $2,119,000 USD 1.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%